• NOTA-labeled somatropins were synthesized using different NOTA:protein ratios.
INTRODUCTION
The recent successes of biopharmaceuticals are changing the focus of the pharmaceutical industry.
The US Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) approved 39 new drugs in 2012, whereof six represent biologics license applications (BLAs) [1] . By 2015, it is even expected that 50% of the newly approved drugs will be biologics [2] , which further illustrates the importance of the development of new biological entities (NBEs) and bioanalytical tools for the characterization of NBEs and biosimilars towards registration [3, 4] .
Cancer is still the largest therapeutic area nowadays [1, 5] . Tumor targeting in nuclear medicine is based on a target-specific radiopharmaceutical ligand for selective receptor binding in the disease tissue [6] [7] [8] . The targeting biomolecules can be used as therapeutics to deliver a toxic radioactive payload selectively to a tumor site (e.g. I-131 tositumomab or Y-90 ibritumomab), as well as diagnostic agents for non-invasive single photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging (e.g. In-111 Capromab pendetide or In-111 pentetreotide) [9, 10] and playing an important role in cancer management as a form of personalized medicine [9, 11] .
One of the biomolecules of current interest is human growth hormone (hGH). In the late 50s, severe growth hormone deficiencies (GHD) in children were treated by cadaveric pituitary hGH or somatotropin extracts. However, several cases were reported which correlated the use of cadaveric somatotropin with Creutzfeldt-Jakob disease, leading to an abrupt stop of hGH extract treatment [12] . This led to the worldwide regulatory approval of recombinant hGH. Recombinant hGH or somatropin is nowadays used for the treatment of GHD, as well as the treatment of Turner Syndrome and AIDS associated catabolism [13] . Recently, biosimilar somatropin formulations were also globally approved [14] [15] [16] . Moreover, somatropin and analogues are often encountered as spurious/falselylabelled/falsified/counterfeit (SFFC) medicines [17] [18] [19] and drug abuses in sports [20, 21] , agriculture [22] and anti-aging [23] have been reported.
Somatropin can perform its actions by binding with high affinity to the extracellular domains of two identical molecules of human growth hormone receptors (hGHR) [24] [25] [26] [27] , which are widely expressed in liver tissue, but are also aberrantly overexpressed in numerous cancers such as prostate [28, 29] , breast [30] and colon cancer [31] . The potential involvement of the GH system in tumor promotion and progression, which has been critically reviewed in references [32] and [33] , as well as the internalization of the receptor-ligand complex [34] , makes hGHR a potential tumor target for the development of somatropin-based radiopharmaceuticals.
Modifications with bifunctional chelating agents (BFCA) like S-2- (4- fluorescein) [9] .
MATERIALS AND METHODS

Materials and equipment
The p-SCN-Bn-NOTA was purchased from Macrocyclics Inc. (Dallas, TX, USA). Zomacton® 4 mg, (Ferring, somatropin Ph. Eur.) was purchased at the Ghent University Hospital (Ghent, Belgium). The enzymes for peptide mapping, L-1-tosylamide-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin solution and immobilized chymotrypsin solution, were purchased at Pierce (Erembodegem, Belgium) and Sigma Aldrich (Diegem, Belgium), respectively. PD-10 sephadex G-25M columns were obtained from GE healthcare (Diegem, Belgium). Water was purified in-house using an Arium 611 purification system (Sartorius, Göttingen, Germany), yielding ≥ 18.2 MΩ × cm quality water. Other chemicals and solvents were purchased from Merck (Overijse, Belgium), Sigma Aldrich (Diegem, Belgium) or Fischer Scientific (Erembodegem, Belgium), all high quality (>98% purity) and/or HPLC/MS grade.
Freeze-drying was done using a Christ gamma 1-16 LSC freeze dryer (Qlab, Vilvoorde, Belgium).
The HPLC-UV-MS apparatus consisted of a SpectraSystem separations module, a Finnigan LCQ Classic ion trap mass spectrometer in positive ion mode (all Thermo, San José, CA, USA) equipped with a Waters 2487 dual wavelength absorbance UV detector (Waters, Milford, MA, USA) and Xcalibur 2.0 software (Thermo, San José, CA, USA) for data acquisition. For CE-MS, a P/ACE MDQ capillary electrophoresis instrument (Beckman Coulter Inc., Brea, CA, USA) was used for separations, whereas a micrOTOFQ orthogonal accelerated time-of-flight (TOF) mass spectrometer (Bruker Daltonics, Bremen, Germany) was used for detection and identification. included a rinsing step out of 60% 1-propanol, followed by returning to the initial conditions and re-equilibration. ESI was conducted with a capillary voltage of 4.5 kV. Nitrogen was used as the sheath and auxiliary gas; the temperature of the heated capillary was set to 280°C. MS/MS spectra were used for identification and obtained by collision induced dissociation (CID) of the parent m/z, with the relative collision energy set to 35%. UV detection and quantification were performed at 220 nm.
Synthesis
The CE-MS analysis was performed using fused-silica capillaries (800 mm × 50 µm I.D., Polymicro
Technologies, Phoenix, AZ, USA) coated with a bilayer of Polybrene and poly (vinyl sulfonic acid) as described previously [37] . Sample injections were performed at 1 psi for 12 s. and 83 V, respectively. CE-MS data were analyzed using Bruker Daltonics Data Analysis software.
Molecular weight determinations of proteins were performed using the "Charge Deconvolution" utility of the Data Analysis software. Quantification of the conjugates was performed using the construction of an extracted-ion electropherogram. Each detected conjugate showed the same charge state distribution profile, with (M+9H) 9+ and (M+10H) 10+ as most abundant ions. The relative abundance of each conjugate in the analyzed preparation was established by calculating the ratio of the conjugate peak area to the total peak area.
Peptide mapping
The unmodified somatropin (i.e. control) and NOTA-modified somatropins (45 nmol protein) were dissolved in 1000 µL 6 M guanidine HCl, 35 mM tris, 20 mM DL-dithiothreitol at pH 7.5 and incubated for 30 min at 37°C, while shaking at 300 rpm. S-carboxymethylation of cysteine residues was performed by addition of 20 µL of iodoacetate (pH 7.2; 58 mM) and subsequent incubation for 30 min at 37°C (at 300 rpm). 100 µL of DL-dithiothreitol (1 M) was added and mixed. The sample was loaded onto a PD-10 column sephadex G-25M (equilibrated with digestion buffer consisting of 10 mM ACES, 20 mM CaCl 2 , pH 7.0). After collection of the protein fraction in 2.0 mL, 1.0 mL was transferred into 100 µL of immobilized TPCK-treated trypsin solution (20 TAME units) and mixed.
The reaction mixture was incubated for 4 hours at 37°C (300 rpm). For the 3:1 protein sample, 1.0 mL of the protein fraction was transferred to 200 µL of immobilized chymotrypsin solution (8.3 ATEE units) as well, mixed, and incubated for 24 hours at 37°C (300 rpm). After incubation, the solutions were centrifuged at 100 g for 10 sec. 1.0 mL of the supernatant was transferred to 10 µL of formic acid (10% v/v), mixed and centrifuged at 20 000 g for 10 min. The supernatant was analyzed by LC-MS.
ESI was conducted using a needle voltage of 3 kV. Nitrogen was used as the sheath and auxiliary gas 
In silico pKa calculations
Structure-based pKa calculations were performed using the Adaptive Poisson−Boltzmann Solver (APBS version 1.1.0) [38] , in which the pKa per titratable residue is determined as the sum of an unperturbed model value [39] and a perturbational shift reflecting the transfer of the amino acid from solution to the protein environment. The latter is calculated through a rigorous free energy cycle and numerical solution of the linearized Poisson−Boltzmann equation [40] . All calculations were carried out at 298.15 K with a solvent dielectric constant of 78.54 and a protein dielectric constant of 20. pKa calculations were performed on the protein structure only, taken from the last frame of a molecular dynamics (MD) simulation. Appropriate PQR files were generated with the aid of PDB2PQR version 1.4.0 [41, 42] , employing the CHARMM [43, 44] parameterization.
Prior to the pKa calculations, structural calculations were performed using NAMD version 2.6 [45] and the CHARMM forcefield [43, 44] , starting from the 1HGU crystal structure of the human somatotropin [46] . Optimal protonation states were assigned and missing atoms were added. In an ensuing 5000-step conjugate-gradient energy minimization only these atoms were allowed to move, while constraining all other atoms. Twelve amino acids were then mutated in accordance with the somatropin sequence (Q11D, E29Q, A47N, A50T, Q66E, A67T, Q75E, G91Q, D109N, A138I, A144S, A148T) followed by 5000 steps of conjugate-gradient minimization of the atoms of the mutated residues only. The resulting structure was solvated with 20.442 water molecules in an orthogonal box of size 83.1x86.5x95.1 Å 3 and made charge neutral by adding six sodium ions. The entire structure was subject to energy minimization (5000 conjugate gradient steps) with constraints on all protein atoms. This was followed by an unconstrained MD equilibration run of 50 ps (1 fs time step) in the NVT ensemble at 300 K, employing Langevin dynamics with a damping coefficient of 1 ps -1 to control temperature. Electrostatics were treated with particle-mesh Ewald (PME) [47] . A shortrange cutoff of 14 Å was maintained, and electrostatic and van der Waals interactions were gradually switched off starting from 10 Å. Neighbor lists were updated every 2 fs using a cutoff of 16.5 Å. The final production MD simulation totaled 1 ns with identical parameters. 
Gallium labeling and quality control
RESULTS AND DISCUSSION
Production of NOTA-somatropin
Successful clinical use demands that a bifunctional chelating agent (BFCA) is both capable of maintaining a stable complex with a radionuclidic metal in vivo, e.g. Ga(III), while possessing a functional group which can be used for protein attachment. p-SCN-Bn-NOTA is a well-established hexadentate BFCA, forming an exceedingly stable complex with Ga(III) (log K = 30.98) [48] . The isothiocyanate function (R-NCS) allows formation of stable thiourea bonds at alkaline pH with free amines (Fig. 1) . Somatropin has nine potential reaction sites (lysine's ε-amino residues) for the addition of p-SCN-Bn-NOTA. We have used a pH of 9.0 during synthesis: higher pH values will tend to accelerate the degradation of somatropin [49] and the R-NCS reagent, while lower pH values will lower the concentration of the free base form of the amines. These nine sites can lead to heterogeneous product formation consisting of different substitution degrees (i.e. the amount of bound NOTAmolecules per somatropin protein). Moreover, for a somatropin entity that has a single NOTA- molecule attached, the NOTA-moiety may be attached at different amine sites. This creates the potential for a large number of position isomers as the degree of substitution increases ( Fig. 2A ) [50] .
Analytical characterization of the heterogeneous production is very important as special attention must be paid to the lysine residues that are modified, since chemical modification can influence receptor binding and hence, the outcome of biological assays [51] . We applied three different synthesis ratios 
Direct analytical characterization of the products
A single analytical technique for the characterization of biologicals is generally not sufficient [54, 55] .
Therefore, a combination of LC-MS and CE-MS was applied to investigate the NOTA-somatropin products. In the biopharmaceutical field, LC is used for both the assessment of protein batch purity, protein modification (e.g. glycosylation) and aggregation [4, 56] . In combination with MS, precise and complementary information is generated. In this direct analytical approach, intact protein molecular ions generated by electrospray (ESI) or matrix-assisted laser desorption (MALDI) are introduced into the mass analyzer [57] .
We have initially based our method on the related protein test described in the European Pharmacopoeia for somatropin (Ph. Eur. The NOTA-labeling was quantitatively monitored over time for 22 hours for the 3:1 NOTA:somatropin sample using our RP-C 4 method (Fig. 2B) . The complexity of the product composition was confirmed by a decrease of unmodified somatropin and an increase of higher order substitution degrees over time. Steady state was reached after 20 hours of incubation. Using this incubation period during synthesis, the unmodified somatropin was completely absent in the 10:1 NOTA:somatropin sample (Fig. 3A) . The highest yield of the desired mono-and di-NOTAsomatropin (substitution degree +1 and +2) were obtained in the 3:1 sample (58%). Higher order modifications (substitution degree of more than 2) were heavily represented in sample 10:1 (98%). For some substitution degrees, different position isomers could be detected. The total peak recovery (peak balance) was found between 90-110%, confirming the analytical characterizing capacity of the method. Our findings were confirmed by CE-MS (Fig. 3B) , a technique also included in the somatropin monograph of the European Pharmacopoeia (Ph. Eur. 8.0: 01/2008:0951) [58] . In CE, the separation is based on charge differences [59] , in our case a loss of one positive charge of lysine with the simultaneous addition of negative charges of NOTA, whereas in RP HPLC mainly the decrease in hydrophobicity due to the attachment of NOTA leads to the separation [56] . Overall, the 1:1 and 3:1 samples show similar degrees of somatropin modification as measured with CE-MS compared to LC-MS (Fig. 3) . In the 10:1 sample, CE-MS revealed somatropin with NOTA substitution degrees ≥5
(amounted for 3%). As these highly polar compounds end up in the LC dead time they were not detected, whereas in CE they migrate later and, therefore, could be detected. In general, we can conclude that both CE-MS and LC-MS techniques lead to similar conclusions regarding the extent of modification. However, higher order substitution degrees are detectable using CE-MS.
Peptide mapping of the NOTA-modified somatropins
The current gold standard in protein characterization is the "bottom-up approach". This method relies on the digestion of a mixture of proteins of interest and subsequent analysis of the digested peptides by LC-MS. All peptides were identified based on their peptide mass fingerprint (m/z value) and CID fragmentation pattern, thereby establishing the validity of these patterns for peptide identification and structural elucidation of the protein modification (Fig. 4) . Peptides containing the NOTA-label are characterized by a mass increase of 449.52 Da and specific NOTA-losses in their CID spectra ( Fig.   4A-B) . Another observation made was the lower residual protein quantity upon the different modification and chelation steps, which are each followed by a desalting step and a lyophilisation step in case of NOTA-modification. Therefore, the UV absorption upon NOTA-modification (going from A to B) is lower.
The monograph of somatropin in the European Pharmacopoeia (Ph. Eur.) includes a peptide mapping method using trypsin (Ph. Eur. 8.0: 01/2008:0951) [58] . It is commonly known that trypsin is a specific protease that cleaves at the c-terminal of arginine and lysine residues [60] . This yields theoretically 21 peptide fragments for somatropin (PeptideCutter [61] ). However, trypsin skips lysine cleavage sites when NOTA-modifications are present, e.g. for the NOTA-labeled Lys-158 protein fragment (fragment 146-164) one trypsin cleavage site was missed. The individual peptides with NOTA-modification are given in Table 1 . They represent modifications of lysine residues at Lys-70, Lys-158, Lys-140 and Lys-172, with Lys-70 found in all samples. The sequence coverage of the trypsin digest was more than 95% for the control (i.e. unmodified somatropin sample) and more than 90% for the NOTA-labeled somatropin samples; all lysine residues were recovered (100% lysine coverage) in the control and NOTA:somatropin samples. The NOTA-Lys-70 modification yield was very high in all samples (94-100%). The Lys-70 coverage amounted for 6% (i.e. the ratio between number of peptides containing Lys-70 and number of peptides containing a Lys residue), which is half of the theoretical specific Lys coverage of 11%. This means that relatively less fragments with Lys-70
were recovered compared to the other Lys-peptides. Indeed, for Lys-140, Lys-158 and Lys-172, the specific lysine (LysX) coverage was more than 11%. Not only in HPLC but also in the hydrolysis step of the peptide mapping, orthogonal systems can be used to further analyze the modification yield from the different molar ratios. Chymotrypsin mainly cleaves peptide bonds in which the carboxyl group is contributed by phenylalanine, tryptophan and tyrosine, theoretically also yielding 21 fragments for somatropin [61] . In addition, leucine and methionine may be cleaved as well, although at a much lower rate. This would theoretically yield 54 somatropin fragments [61] . Results are given in S.I.1. A relatively low overall sequence coverage was obtained after chymotryptic peptide mapping of control and NOTA-modified samples (below 80%).
The Lys-70 residue was found in 37% of the Lys containing peptide fragments, i.e. a much higher Lys-70 coverage compared to trypsin-cleaved peptide mapping, but at the expense of Lys-158 with a LysX coverage of 0%. The NOTA-LysX distribution yield in sample 3:1 NOTA:somatropin was also found mostly on Lys-70 (86%) followed by Lys-140 (14%), with NOTA-LysX modification yields of 50% and 67%, respectively. The use of chymotrypsine therefore gives another perspective on the modification yield compared to trypsine (94% vs 50% for Lys-70), confirming the structural information. Similar conclusions were also obtained with an enzyme combination of trypsin and chymotrypsin (see S.I.2.). The use of S. aureus V8 protease was not suited for peptide mapping: the sequence coverage was below 40% and the lysine coverage amounted 22% for NOTA-labeled somatropin and control (see S.I.3.).
Our data indicate that Lys-70 is a hotspot for NOTA-modification (Table 1) , which was also suggested by Sakal et al. after modification of somatropin with fluorescein isothiocyanate (FITC) [62] . Our in silico ab initio pKa calculations revealed that the Lys-70 residue has a lower pKa value (pKa = 8.3)
than the other eight Lys-residues and is therefore more reactive under our modification conditions (Fig. 5 ). In addition, Lys-70 is positioned outside the binding pocket of the somatropin:hGHR interaction: modification of this lysine residue will therefore not directly interfere with receptor binding (Fig. 5 ). According to our data, i.e. the NOTA-LysX distribution yield and modification yield, we conclude that Lys-70 followed by Lys-158 are most reactive towards p-SCN-Bn-NOTA and Lys-140 and Lys-172 are the less reactive lysine residues. Except for Lys-172, all found lysine residues lie outside the binding pocket with the receptor. 
Analysis of gallium labeled NOTA-somatropin
For the complexation of gallium in NOTA, two times molar excess of gallium was used compared to the used amount of p-SCN-Bn-NOTA during NOTA:somatropin synthesis. Similar results as for NOTA-modified somatropin (section 3.2) were obtained: the overall sequence coverage after tryptic peptide mapping was 96%, with 100% lysine coverage. Tryptic peptide mapping of gallium labeled NOTA-somatropin demonstrated that all NOTA molecules were complexed with gallium ( Fig. 4C) , resulting in labeling efficiencies of 100%.
CONCLUSION
The presence of multiple reactive sites on biomolecules towards chemical modifications during conjugation reactions can have a great impact on the product composition, and hence, the biological activity. Therefore, it is important to analytically characterize the products originating from different synthesis procedures. Direct analytical and bottom-up approaches were used to profile the different modified somatropin proteins and demonstrated that higher amounts of p-SCN-Bn-NOTA during synthesis led to a heterogeneous product with higher order substitution degrees, as well as different position isomers. The 1:1 NOTA:somatropin synthesis procedure yielded the highest mono-NOTAsomatropin fraction (42%) with less higher order substitution degrees (≥2 NOTA, 12%); Lys-70 was found to be the modification hotspot towards p-SCN-Bn-NOTA. We conclude that Lys-70 followed by Lys-158 are most reactive towards p-SCN-Bn-NOTA and Lys-140 and Lys-172 are the less reactive lysine residues. Except for Lys-172, all found lysine residues lie outside the binding pocket with the receptor. The synthesis of NOTA-somatropin is a suited synthesis procedure for the production of target-specific radiopharmaceuticals for further investigation of the treatment and visualization of growth hormone receptor overexpressing cancers.
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